InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Releases Financial Report, Corporate Updates
June 30, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, is reporting on its fiscal year, which ended March 31, 2022. Highlights from the report include the company starting to ship its sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its UK […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Secures $5M in Non-Dilutive Funding
May 23, 2022
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs. The company today announced that it has secured $5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements. Under the current financing, existing debt repayments […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate in H.C. Wainwright Global Hybrid Investment Conference
May 19, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, and its CEO Dr. Faz Chowdhury will be attending the upcoming H.C. Wainwright Global Hybrid Investment Conference. The conference is slated for May 23–26, 2022, in Miami Beach, Florida. Chowdhury has been invited […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) UK licensee, MySugarWatch, Begins Direct-to-Consumer Campaign in Daily Mail
May 17, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that MySugarWatch, its UK licensee is launching a direct-to-consumer campaign in “Daily Mail,” one of the United Kingdom’s largest daily newspaper. The campaign is part of MySugarWatch’s large-scale awareness efforts focused on […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Launch of Physician-Focused Ads as Part of Large-Scale Campaign Around sugarBEAT(R)
May 3, 2022
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that its U.K. licensee, MySugarWatch, as part of a large scale awareness campaign for the company’s sugarBEAT non-invasive continuous glucose monitor, has launched a series of ads in […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at Planet MicroCap Showcase 2022
April 25, 2022
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that it will be presenting at the Planet MicroCap Showcase 2022, which is slated to take place from May 3-5, 2022, at the Bally’s Hotel & Casino in […]
InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Technologies Stand Distinct
April 1, 2022
Nemaura Medical (NASDAQ: NMRD) recently launched its MiBoKo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear and cost-effective. “Sensors developed by Nemaura stand apart from competitor devices that employ microneedles coated with enzymes and polymers — some of which require insertion for up […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming Maxim Group 2022 Virtual Growth Conference
March 25, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be attending and participating at this month’s Maxim Group 2022 Virtual Growth Conference. NMRD CEO Dr. Faz Chowdhury will be providing an overview of the company that will […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Valuable AI-Powered Insights to Diabetes Market
March 22, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company developing and commercializing non-invasive wearable diagnostic devices, is positioned to offer innovative solutions to a rapidly growing market. According to a recent report released by the International Diabetes Federation (“IDF”), diabetes is “spiraling out of control.” According to the report, 537 million adults live with diabetes, a […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Commercialization Phase of Its Corporate Development, Recognizes First-Ever Revenues
March 18, 2022
Nemaura Medical (NASDAQ: NMRD) recently announced its Q3 FY 2022 results for the three months ended Dec. 31, 2021. The company reported revenues of $183,628 due to the initial shipments made over the past quarter of sugarBEAT(R) CGM devices to MySugarWatch, the company’s U.K. licensee. The order marked the inaugural revenues in Nemaura Medical’s history, […]
Metabolic Health Diseases Rising Globally, Nemaura Medical Inc. (NASDAQ: NMRD) Aims to Disrupt Market with Non-Invasive, Cost-Effective IoT Devices, Mikobo Coaching Program
March 17, 2022
Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, stroke Companies in diagnostic space posting record revenues, double-digit YOY increases Nemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology, companion mobile application and coaching programs Competitor devices use microneedles coated with enzymes and polymers that can cause discomfort, trauma, […]
InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Revolutionary sugarBEAT(R) CGM Device Met with Early Success
March 11, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company, has sought to develop and offer economical, compact and convenient non-invasive devices that could alleviate the pain associated with frequent skin pricking among diabetic patients. The devices also simultaneously promote routine glucose testing in a bid to control blood glucose levels more effectively. Nemaura offers two flagship […]
Nemaura Medical Inc.’s (NASDAQ: NMRD) sugarBEAT(R) Wearable CGM Device Targets Billion-Dollar Global Diabetes Market
March 2, 2022
Global diabetes-related healthcare expenses are estimated at $966 billion in 2021 A recent report reveals 537 million adults currently live with diabetes, projected to rise to 643 million by 2030 and 783 million by 2045 Glucose intake is an important factor in diabetes management, prevention and reversal NMRD’s sugarBEAT(R) wearable is a non-invasive, flexible CGM […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Recognized as Innovator of the Year, Awarded Top Honors for Innovation in MedTech, Life Sciences
February 28, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its receipt of the top award as Innovator of the Year at the LeicestershireLive Innovation Awards 2022 held on Feb. 24, 2022. In addition, the company was awarded top honors […]
Nemaura Medical Inc. (NASDAQ: NMRD) Publishes 3QFY2022 Results; Company Reports its Inaugural Quarterly Revenues
February 25, 2022
Nemaura Medical has recently reported its 3QFY2022 (4QCY2021) results, with the company recognizing its inaugural revenues of $183,628 over the quarter The company also announced that it held $23 million in cash reserves as of the end of the quarter, which should amply cover its cash requirements over the coming months Nemaura Medical seized upon […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Producing What Was Thought to Be Implausible
February 23, 2022
Nemaura Medical (NASDAQ: NMRD) has long focused on its corporate mission to develop non-invasive wearable diagnostic devices designed to help diabetic and near-diabetic patients monitor blood glucose levels by measuring blood markers at the surface of the skin. Its revolutionary sugarBEAT(R) constant glucose monitoring (“CGM”) device provides users with non-invasive glucose monitoring. Recently, the company […]
Nemaura Medical Inc. (NASDAQ: NMRD) Seeks to Provide Non-Invasive Glucose Monitoring Solutions to Millions of Patients Worldwide
February 17, 2022
Over 420 million people around the globe currently have diabetes, with the figure set to rise by 55% over the next 25 years Millions of patients required to measure their blood glucose levels daily to accurately determine their insulin dosage amounts Nemaura Medical has launched two constant glucose monitoring solutions – the SugarBEAT(R) device as […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Reports Financial Results, Business Updates for Q3 2022
February 14, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has released its Q3 financial results and business updates. The company noted that, for the three-month period ending Dec. 31, 2021, highlights included the shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its […]
Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference
February 14, 2022
NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022 Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion NMRD’s sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to use NMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Appoints New COO in Readiness for Manufacturing and Distribution Scale-Up, Commercialization Phase of Growth
February 11, 2022
Nemaura Medical (NASDAQ: NMRD) recently appointed Dr. Arash Ghadar as its chief operating officer. Dr. Ghadar brings decades of health care and technical experience to Nemaura, including from his previous role as technical director at Datalink Electronics and his current director role at Medilink Midlands. “Ash will play an important role at Nemaura as we […]
Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate
February 9, 2022
The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026 Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three years Nemaura Medical has […]
InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Miboko Launch Leveraging ‘Most Reliable Gateway Toward Wider Adoption of Preventative Health Maintenance Practices’
February 3, 2022
Nemaura Medical (NASDAQ: NMRD) recently announced it would launch Miboko, its new metabolic health program, for employers and insurers. “The Miboko application, a service offering that has been in development over the past 18 months, uses a non-invasive glucose sensor to measure and monitor users’ blood sugar levels, which are based on glucose tolerance or […]
Nemaura Medical Inc. (NASDAQ: NMRD) Appoints Technical Healthcare Specialist Dr. Arash Ghadar as COO
January 28, 2022
NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experience Dr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certification NMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, recently completed initial shipment to UK licensee MySugarWatch Limited MySugarWatch Limited aims to market devices […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Marks History Making Milestone with Initial Shipment of CGM Devices
January 27, 2022
Nemaura Medical (NASDAQ: NMRD) is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible and affordable continuous glucose monitoring (“CGM”) device. “As part of its marketing strategy, NMRD recently completed an initial shipment of sugarBEAT devices to MySugarWatch Limited, its U.K. licensee. MySugarWatch Limited intends to market sugarBEAT via a subscription-based diabetes coaching and […]
Nemaura Medical Inc. (NASDAQ: NMRD) Commence Rollout of Their Miboko Application; Company Targets Employers & Insurers to Ensure Broad Commercial Distribution
January 24, 2022
Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently announced the rollout of its Miboko application by targeting insurers and employers In 2019, over $760 billion was spent on diabetes-related health care, equating to $9,000 per diabetic patient compared to $1,600 for a non-diabetic individual The Miboko […]
Nemaura Medical Inc. (NASDAQ: NMRD) Firmly Positioned in Growing Diabetes Tech Market With Recent CGM Shipment to UK Licensee
January 20, 2022
Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Launches Miboko – a New Metabolic Health Program
January 13, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of Miboko for employers and insurers. Miboko is a new metabolic health program using a non-invasive glucose sensor along with an AI mobile application. The company, aligned with […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names Industry Veteran as COO
January 10, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has appointed Dr. Arash (Ash) Ghadar as chief operating officer. Currently a non-executive director at Medilink Midlands, Ghadar served for 10 years as the technical director of London-based Datalink Electronics (Datalink), where he […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at H.C. Wainwright Bioconnect Conference
January 7, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Dr. Faz Chowdhury will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference. The event is slated to take place on Jan. 10-13, 2022, […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Marks True Milestone in Development, Growth
January 4, 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently completed the initial shipment of its sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited. “MySugarWatch will market the sugarBEAT product under the MySugarWatch(R) brand and has developed […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Solutions to Empower People to Take Charge of Their Health, Well-Being
December 29, 2021
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved to […]
Nemaura Medical Inc. (NASDAQ: NMRD) Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee
December 22, 2021
Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licensee The initial shipment, which comprised 5,000 CGM devices and 200,000 sensors, is expected to result in follow-on monthly orders of up to 2 million sensors and 15,000 CGM devices over the next two years Following […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Positioned to Benefit from Growth in CGM Market
December 13, 2021
Nemaura Medical (NASDAQ: NMRD) has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and health care observations. With the global continuous glucose monitoring (“CGM”) devices market expected to reach $19.04 billion in 2028 from $4.11 billion in 2020, according to an analysis by Reports and […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Initial Shipment of CGM Devices to MySugarWatch Licensee
December 7, 2021
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that it has completed its initial shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited, previously DB Ethitronix Limited. According to the update, MySugarWatch will […]
Nemaura Medical Inc. (NASDAQ: NMRD) Helping Diabetic Individuals Safeguard Themselves From COVID-19
December 7, 2021
1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing Nemaura Medical is a medical technology company focused […]
Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited
December 2, 2021
NMRD releases fiscal Q2-2021 results, provides business update Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector Nemaura Medical (NASDAQ: […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) CEO to Present at Benzinga Global Small Cap Conference
November 30, 2021
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Faz Chowdhury, Ph.D., will present at the Benzinga Global Small Cap Conference. The event is scheduled to be held virtually from Dec. 8-9, 2021. Dr. Chowdhury will […]
Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market
November 18, 2021
The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028 The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growth Nemaura Medical’s sugarBEAT device allows individuals to make adjustments to diet and activity that can significantly change their lives According to a recent […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2 2022 Financial, Business Report
November 15, 2021
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has reported its financial and business updates for the second quarter of FY2022, the period ended Sept. 30, 2021. Notable highlights include the launch of Miboko, the company’s beta mass-market metabolic health […]
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Extending Proprietary Technology, Programs Beyond Traditional Diabetes Market
November 9, 2021
Nemaura Medical (NASDAQ: NMRD), a cutting-edge medical technology company, recently conducted the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI-based mobile application. The MiBoKo application is designed to measure and monitor the user’s metabolic health scores based on glucose tolerance and insulin resistance. […]